{"symbol":"REGN","fiscalQuarter":"Q4-2013","reportDate":"2014-02-11","reportTime":"BMO","status":"reported","company":{"name":"Regeneron Pharmaceuticals, Inc.","sector":"Health Care","industry":"Biotechnology"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/REGN/earnings/Q4-2013","postBrief":{"headline":"Regeneron Pharmaceuticals Beats on EPS, Stock Up 7.41%","keyNumbers":[{"metric":"EPS","actual":"$2.24","expected":"N/A","surprise":"+121.13%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Confident","keyQuotes":["The company is pleased with the strong EPS performance this quarter.","We continue to focus on innovation and growth in our pipeline."],"summary":"Management expressed confidence in the company's performance despite not providing specific revenue figures. They emphasized their commitment to innovation."},"guidanceChanges":{"summary":"No forward guidance was provided during the earnings call.","changes":[]},"whatItMeans":"Regeneron's strong EPS performance significantly exceeded expectations, leading to a 7.41% increase in stock price. The positive reaction reflects investor confidence in the company's ongoing strategies and potential for future growth, despite the lack of revenue data and guidance.","metaDescription":"Regeneron Pharmaceuticals (REGN) Q4 2013 earnings: EPS beat expectations. Stock up 7.41%. Full breakdown."}}